The regulator had earlier asked the drug makers and groups to share details regarding the price movement, production details and inventory of active pharmaceutical ingredients (APIs) and key starting material (KSM) of 58 crucial APIs that are imported from China so as curb possible shortages of molecules.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3cRDx2N
via IFTTT
0 comments:
Post a Comment